Veteran healthcare investor Matt Cohen joins Arrowhead (ARWR) board with $887K RSU grant
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Arrowhead Pharmaceuticals, Inc. announced that its Board of Directors appointed Dr. Matt Cohen, M.D., M.B.A., as a director, effective June 12, 2026. Dr. Cohen brings more than 25 years of healthcare investing and portfolio management experience, including senior roles at JP Morgan Asset Management and Vida Ventures.
He will receive standard non-employee director compensation plus a sign-on grant of restricted stock units valued at $887,000, scheduled to vest over three years. The company states there are no family relationships or appointment-related arrangements with other persons, and Dr. Cohen will enter into Arrowhead’s standard indemnity agreement.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 5.02, 9.01
2 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Sign-on RSU grant: $887,000 restricted stock units
Effective appointment date: June 12, 2026
Filing sign date: June 16, 2026
3 metrics
Sign-on RSU grant
$887,000 restricted stock units
One-time grant to Dr. Matt Cohen, vesting over three years
Effective appointment date
June 12, 2026
Date Dr. Matt Cohen’s directorship at Arrowhead became effective
Filing sign date
June 16, 2026
Date Arrowhead’s authorized officer signed the 8-K
Key Terms
restricted stock units, non-employee directors, indemnity agreement, emerging growth company
4 terms
restricted stock units financial
"In addition, in connection with his appointment, Dr. Cohen will receive a sign-on grant of restricted stock units valued at $887,000."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
non-employee directors financial
"Dr. Cohen will receive standard compensation and equity awards available to non-employee directors of the Company."
Non-employee directors are board members who do not work for the company as salaried employees and usually do not hold day-to-day management roles. They act like outside referees or independent coaches, providing oversight, asking tough questions, and protecting shareholders’ interests; investors care because these directors help ensure management is accountable, reduce conflicts of interest, and influence decisions that affect company strategy and long-term value.
indemnity agreement regulatory
"Dr. Cohen will also enter into the Company’s standard form indemnity agreement."
emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
What did Arrowhead Pharmaceuticals (ARWR) disclose in this 8-K filing?
Arrowhead Pharmaceuticals reported the appointment of Dr. Matt Cohen as a new director effective June 12, 2026. The filing outlines his extensive healthcare investing background, his compensation package, including a $887,000 RSU grant, and confirms standard governance arrangements and no family relationships.
Who is Dr. Matt Cohen, the new director at Arrowhead Pharmaceuticals (ARWR)?
Dr. Matt Cohen is a seasoned healthcare investor with over 25 years of experience. He serves as Managing Director at Vida Ventures and previously led major JP Morgan Asset Management healthcare and growth funds, following earlier analyst roles at healthcare-focused hedge funds and a surgical residency.
What compensation will Dr. Matt Cohen receive as an Arrowhead (ARWR) director?
Dr. Cohen will receive the standard non-employee director compensation and equity awards under Arrowhead’s director program. In addition, he will receive a one-time sign-on grant of restricted stock units valued at $887,000, which are scheduled to vest over three years from grant.
Are there any special arrangements linked to Dr. Matt Cohen’s appointment at ARWR?
Arrowhead states there is no arrangement or understanding with any other person under which Dr. Cohen was appointed. The filing also notes there are no family relationships with existing directors or executive officers, and he will sign the company’s standard form indemnity agreement.
How does Dr. Matt Cohen’s background relate to Arrowhead Pharmaceuticals (ARWR)?
Dr. Cohen’s background centers on healthcare investing and portfolio management across small, mid, and large-cap companies. His experience overseeing multi-billion-dollar JP Morgan healthcare and growth funds suggests familiarity with biopharmaceutical business models, potentially supporting Arrowhead’s board in capital markets and strategic discussions.